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Abstract
This work consists of six parts based on seven manuscripts dealing with some aspects of genetic counselling for
BRCA1 mutation carriers. It was demonstrated that the risk of breast and ovarian cancer in first-degree relatives
of BRCA1 mutation carriers depends on the type of mutation and is higher in the younger generation. It was
also shown that risk of breast cancer, but not of ovarian cancer, is related to cancer type of the proband. These
factors should be taken into account when assessing risk of breast and ovarian cancer in relatives of BRCA1
mutation carriers. It was observed that longer breast-feeding, physical activities delaying menarche, preventive
oophorectomy, administration of tamoxifen to patients with intact genital tract, and use of contraceptives reduce
the risk of breast and ovarian cancer. All these possibilities should be presented to BRCA1 mutation carriers
within the framework of cancer risk reduction options. It was also observed that there may be some preference
in transmission of the mutant allele to female offspring of BRCA1 founder mutation carriers. Environmental
factors appear also to interfere with transmission. The male to female ratio in offspring of BRCA1 mutation
carriers is the same as for the general population. As for the consequences of simplified two-stage genetic
counselling, the first psychological reaction of a female to the fact that she is a carrier of the BRCA1 mutation
is negative. However, understanding that the risk of cancer is high persuades the woman to embrace preventive
options. 98% of BRCA1 mutation carriers disclosed during population screening initiated and promoted by the
media are convinced of the value of genetic testing. Simplified two-stage genetic counselling appears to be 
a useful approach promoting increased turnout for BRCA1 mutation testing.
Introduction
Genetic counselling is a process which should
explain to the patient all problems caused by
development of hereditary disease in the family or risk
of such disease [1]. Within counselling the patient
should obtain full information about: the disease, its
course, possibilities of treatment, genetics, risk of
disease for particular family members including
planned/unborn children, proceeding (which takes into
account actual knowledge, convictions, life priorities)
which allow to apply optimal prophylactics, treatment
and adaptation to actual life situation [1, 2]. 
Dynamic development of molecular genetics made
possible the diagnosis of a large number of diseases
which hereditary background was until recently
unknown. Hereditary neoplasms including breast and
ovarian cancers belong to this group of disorders. The
oldest report on familial breast cancer was made 
in about 100 BC in the medical literature of ancient
Hereditary Cancer in Clinical Practice 2007; 5(1)4
Jacek Gronwald
Rome [3]. The first report on familial aggregation of
breast cancer in modern times was published in 1866
by Broca, who described 10 cases of breast cancer in
four generations of his wife’s family [4]. However, only
in the middle of the 1990s was it proved at a molecular
level that a significant number of breast and ovarian
cancers have hereditary monogenic aetiology [5, 6]
and testing of BRCA1 and BRCA2 mutations became
a common diagnostic tool to identify persons with high
risk of these cancers. It has been estimated that in
BRCA1 or BRCA2 carriers the risk of breast cancer
reaches up to 80%, and of ovarian cancer 40% [7].
But, what is more important, early prophylactics allow
this risk to be decreased to levels slightly exceeding
population risk [8-10]. In Poland, thanks to the
detection of founder mutations in the BRCA1 gene [11],
which constitute a very high ratio of all detectable
BRCA1 and BRCA2 mutations [11-16], as well as
setting up a network of hereditary cancer units,
diagnosis of persons with high risk of breast/ovarian
cancers has become relatively cheap, common and in
this way very effective. In this aspect we are one of the
best diagnosed societies and up to now in the Centre
of Szczecin alone about 3500 BRCA1 and BRCA2
carriers have been diagnosed. Detection of carriers
creates the need for full genetic counselling of the
highest standard. 
In this work the results of studies on selected aspects
of genetic counselling in BRCA1 carriers have been
described. 
Objectives
1. Assessment of the effect of mutation and tumour
location in probands on the risk of breast and ovarian
cancer in relatives of BRCA1 mutation carriers.
2. Assessment of the effect of some extra-genetic
factors, including age at menarche, parity, duration
of breast-feeding, preventive oophorectomy, oral
contraceptive use, cigarette smoking and coffee
consumption on the risk of breast/ovarian cancer
in BRCA1 mutation carriers from Poland.
3. Assessment of the effect of tamoxifen on the risk of
contralateral breast cancer in BRCA1 and BRCA2
mutation carriers treated for cancer.
4. Assessment of the probability of transmission of the
mutant BRCA1 allele to offspring of the mutation
carrier.
5. Assessment of the male to female ratio in offspring
of BRCA1 mutation carriers.
6. Assessment of psychological and medical
consequences of simplified two-stage genetic
counselling in females appearing for BRCA1 gene
mutation testing.
Material, methods and results
Assessment of the effect of mutation and tumour location 
in probands on the risk of breast and ovarian cancer 
in relatives of BRCA1 mutation carriers
(based on publication: Gronwald J et al. Cancer risk in first degree
relatives of BRCA1 mutation carriers: effects of mutation and
probands disease status. J Med Genet 2006; 43: 424-428)
Breast and ovarian cancer risk in BRCA1 mutation
carriers reach up to 80% and 40%, respectively [7].
However, it is not precisely known which factors
influence BRCA1 penetrance. Therefore estimation of
cancer risk for a patient with a particular mutation is
difficult. Possibly, with mutation additional modifying
factors are inherited which influence cancer risk. In this
scenario, it should be expected that risk is influenced
if the proband was affected with breast or ovarian
cancer. There is also a lack of precise data on how
mutation type influences BRCA1 gene penetrance. 
Materials and methods
In the course of a national breast cancer survey we
identified 4596 women diagnosed with breast cancer at
the age of 50 or below at one of 18 centres in Poland
from 1996 to 2003 We were able to obtain a DNA
sample for BRCA1 analysis from 3568 of these women.
A total of 609 patients with ovarian cancer were
interviewed from 1999 to 2004 at eight centres in Poland.
The three Polish founder BRCA1 mutations (5382insC,
c61G, 4153delA) were identified in 273 cases. A mutation
was present in 198 patients with breast cancer and 
75 patients with ovarian cancer.
We estimated the age-specific breast, ovarian and
total cancer risks for first-degree relatives of mutation
carriers for each mutation separately, using Kaplan-Meier
survival analyses. Patients were considered to be at risk
of cancer from birth until either the development of
cancer, death from another cause or the date of patient
interview. Penetrance curves were compared for mothers
and sisters. The study was approved by the ethics board
of the Pomeranian Medical University.
Results 
The risk of breast cancer for all female first-degree
relatives of all mutation carriers was estimated to be
33%, and the ovarian cancer risk 15%. The cumulative
risks of cancer among first-degree relatives of the
BRCA1 mutation carriers are shown in Table 1.
We observed moderate differences in cancer risk
for the subgroups of relatives with each of the three
different mutations (Tables 1 and 2).
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Table 1. Estimated cumulative risk of breast, ovarian and other cancer in first-degree relatives of BRCA1 founder mutation carriers
Parameters Cancer site BRCA1 First-degree Cancer risk Cancer risk
in relative mutation type relatives to age of 50 to age of 75
with cancer/total
5382insC 60/557 0.15 0.29
breast
C61G 32/226 0.23 0.46
4153delA 8/68 0.25 0.25
total 100/851 0.18 0.33
5382insC 29/557 0.04 0.17
ovary
C61G 3/226 0.01 0.05
4153delA 6/68 0.08 0.38
Females
total 38/851 0.03 0.15
5382insC 22/557 0.03 0.15
other
C61G 17/226 0.05 0.36
4153delA 1/68 0.02 0.02
total 40/851 0.04 0.19
5382insC 111/557 0.22 0.61
any
C61G 52/226 0.29 0.87
4153delA 15/68 0.36 0.66
total 178/851 0.25 0.67
5382insC 47/553 0.03 0.36
Males any
C61G 16/193 0.05 0.33
4153delA 7/70 0.00 0.39
total 70/816 0.03 0.35
In the Cox proportional hazard model, the breast
cancer risk for relatives of women with the missense
mutation C61G was about 40% higher than that
conferred by the more common mutation 5382insC.
Differences in risk with different mutations were also
seen for ovarian cancer. Only 5% of the female
relatives of the C61G mutation carriers were affected
with ovarian cancer, and this was three times lower
than the risk relative to the 5382insC mutation. Risk of
ovarian cancer in first-degree relatives of 4153delA
carriers was 38% – it was almost twice as high as in
relatives of 5382insC carriers.
Table 2. Cancer risk in relatives depending on type of mutation in proband
Mutation in proband Breast cancer Ovarian cancer Any cancer
RR 95% CI p RR 95% CI p RR 95% CI p
5382insC (n = 557) 1.00 1.00 1.00
4153delA (n = 68) 1.12 0.53-2.34 0.77 1.85 0.77-4.47 0.17 1.17 0.68-2.01 0.58
C61G (n = 226) 1.44 0.93-2.21 0.10 0.28 0.09-0.93 0.04 1.28 0.92-1.78 0.15
RR – relative risk; CI – confidence interval; p – statistical significance; n – number of cases.
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Table 3. Cumulative risk of breast and ovarian cancer in mothers and sisters of probands with BRCA1 founder mutations
Cancer site Type of relative Number of first-degree Cancer risk to age of 50 Cancer risk to age of 75
in relative relatives with cancer
sisters 57/356 0.27 0.42
Breast mothers 41/254 0.10 0.25
total 100/851 0.18 0.33
sisters 18/356 0.06 0.21
Ovary mothers 20/254 0.01 0.12
total 38/1158 0.02 0.15
We compared the risk of cancer in sisters and
mothers of the probands to establish if the risk appears
to be changing with time. For both breast and ovarian
cancer the lifetime risk for sisters exceeded that of
mothers (Table 3).
Risk level was analyzed also with respect to cancer
type in the proband. It was observed that breast cancer
risk in first-degree relatives of a proband with a BRCA1
mutation is significantly higher if the proband was
affected with breast cancer than affected with ovarian
cancer, whereas ovarian cancer risk in first-degree
relatives was similar if the proband was affected with
breast or ovarian cancer (Table 4). 
Assessment of the effect of some extra-genetic factors,
including age at menarche, parity, duration of breast-feeding,
preventive oophorectomy, oral contraceptive use, cigarette
smoking and coffee consumption on the risk of breast/ovarian
cancer in BRCA1 mutation carriers from Poland
(based on publication of Gronwald J et al. Influence of selected
lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation
carriers from Poland. Breast Cancer Res Treat 2006; 95: 105-109)
Several environmental and lifestyle factors are
believed to contribute to the development of breast
cancer in the general population and it is of interest
to establish if these factors operate among mutation
carriers as well [17-31]. To evaluate the effects of age
of menarche, parity, breast-feeding, oophorectomy
and oral contraceptive use, as well as smoking and
coffee consumption, on the risks of breast and ovarian
cancer, we conducted a matched case-control study
of Polish women with BRCA1 mutations.
Materials and methods
There were 1482 BRCA1 carriers who completed 
a baseline questionnaire. There were 591 women
affected with breast cancer including 41 who were also
affected with ovarian cancer, 189 women affected with
ovarian cancer and 734 women unaffected with either
cancer. To study the influence of selected factors on the
risk of breast cancer, a matched case-control study was
done. Each case affected with breast cancer was matched
to a healthy control at year of birth (±1 year). After
matching there were 348 breast cancer patients and
matched controls. To study the influence of these factors
on ovarian cancer risk a second matched case-control
study was done. After matching there were 150 ovarian
cancer patients and matched controls. Afterwards,
patients affected with both breast and ovarian cancer,
and the control group were evaluated for the effects of
age of menarche, parity, breast-feeding, oophorectomy
and oral contraceptive use, as well as smoking and coffee
consumption, making proper analyses. McNemar’s test
was used to assess the statistical significance of these
univariate comparisons. Paired t-test was used to
compare continuous variables in cases and controls.
Table 4. Risk of cancer in first-degree relative depending on cancer type in proband
Cancer type in proband Breast cancer Ovarian cancer Any cancer
RR 95% CI p RR 95% CI p RR 95% CI p
Breast cancer 1.00 1.00 1.00
Ovarian cancer 0.58 0.36-0.94 0.03 1.18 0.60-2.31 0.63 0.82 0.58-1.14 0.23
CI – confidence interval; n – number of cases; p – statistical significance; RR – relative risk.
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Table 5. The effect of some factors on the risk of breast cancer in BRCA1 mutation carriers
Parameters Cancer patients Control group OR 95% CI p
(n = 348) (n = 348)
Year of birth 1956.3 1956.7 0.58
Age at diagnosis 41.0
Age at menarche 13.5 13.8 0.9a 0.8-1.0 0.004
Parity 2.1 2.0 1.2b 1.0-1.4 0.02
Cigarette smoking 46% 46% 1.1 0.8-1.5 0.69
Coffee consumption 74% 78% 0.8 0.5-1.1 0.21
Oophorectomyc 2.0% 3.7% 0.4 0.1-1.1 0.08
Breast-feeding:
never 20% 18% 1.0
≤1 year 58% 55% 0.8 0.5-1.3 0.37
>1 year 22% 27% 0.5 0.3-0.9 0.02
Contraceptives:
never 84% 82% 1.0
ever 16% 18% 0.8 0.5-1.2 0.31
ever ≤2 years 6% 4% 0.9 0.5-1.5 0.67
ever >2 years 2% 10% 0.8 0.5-1.4 0.47
CI – confidence interval; n – number of cases; OR – odds ratio; p – statistical significance.
a – per additional year; b – per additional birth; c – prior to diagnosis of breast cancer.
Multivariate odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated by conditional logistic
regression. All p-values were two-tailed and a p-value
of 0.05 was considered to be statistically significant. The
study was approved by the local ethics committee.
Results 
Results of analyses of selected factors on breast
cancer risk are presented in Table 5.
Significant differences between groups of cases and
controls were observed for age of menarche, parity and
breast-feeding. We estimate that each year of delayed
menarche is associated with a 10% decrease in breast
cancer risk (OR=0.9; p=0.004). BRCA1 carriers who
had more children were significantly more likely 
to develop breast cancer; every additional birth
corresponded with a 20% increase in risk (OR=1.2;
p=0.02). Breast-feeding for longer than 1 year was
found to be protective (OR=0.5; p=0.02). Bilateral
oophorectomy also appeared to be protective (OR=0.4);
however, the number of cases and controls who
underwent this procedure was small and the difference
was not statistically significant (p=0.08). We did not
observe significant influences on breast cancer risk for
the other studied factors, including coffee or smoking.
Results of analyses of selected factors on ovarian
cancer risk are presented in Table 6.
A large protective effect was found with ever use of
oral contraceptives (OR=0.4; p=0.04). There were
few long-term pill users in Poland. Women who used
the pill for more than 2 years experienced an 80%
reduction in ovarian cancer risk (OR=0.20; p=0.01),
compared to women who had never used it.
Assessment of the effect of tamoxifen on the risk of contralateral
breast cancer in BRCA1 and BRCA2 mutation carriers treated
for cancer
(based in publication: Gronwald J et al. Tamoxifen and contralateral
breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer
2006; 118: 2281-2284)
The protective effect of tamoxifen has been shown
to reduce the risk of contralateral breast cancer in
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carriers of BRCA1 or BRCA2 mutations [10]. Because
of the small number of carriers, the level of protection
has not been precisely defined. It is also of interest to
establish whether or not there is a protective effect of
tamoxifen in women who have previously undergone
an oophorectomy and to evaluate the protective effect
separately for pre- and postmenopausal women.
Materials and methods
Information on patients with hereditary breast cancer
was submitted to the study centre by investigators at each
of 49 contributing centres in 10 countries. The data centre
received information on a total of 2972 cases of invasive
breast cancer in carriers of pathogenic BRCA1 or BRCA2
mutations. Among the 2972 cases, there were 611 cases
of bilateral breast cancer (20.6%) and 2361 cases of
unilateral breast cancer (79.4%). Bilateral cases were
excluded from the current study if the first cancer was
diagnosed prior to January 1, 1970 (i.e. before tamoxifen
was in use (n=180)), if the contralateral cancer occurred
within 1 year of the diagnosis of the initial breast cancer
(n=47) or if the case was diagnosed with ovarian cancer
at any time prior to the contralateral breast cancer
(n=28). A total of 356 eligible cases of bilateral breast
cancer were identified. Women with unilateral breast
cancer in the registry database were eligible to serve as
controls. Controls were born within 3 years of the birth
date of the case, and were diagnosed with breast cancer
at an age within 2 years of the age of the first diagnosis
of breast cancer of the case. Cases and controls were
carriers of mutations in the same gene (BRCA1 or
BRCA2). Cases and controls were also matched for
oophorectomy (yes/no—1 or more years prior to the age
of second cancer diagnosis in the bilateral case). Women
were ineligible to serve as controls if they were diagnosed
prior to 1970, if they had a contralateral mastectomy or
if they had a diagnosis of ovarian cancer prior to, or
during, the follow-up period. For each bilateral case, we
attempted to identify one or more unilateral control
patients. No woman received tamoxifen prior to the
diagnosis of the initial breast cancer. All of the exposures
in cases and controls are defined for the time period
equivalent to the period before the contralateral cancer
of the matched case. Our study was restricted to living
cases, because it is only possible to perform mutation
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Table 6. The effect of some factors on the risk of ovarian cancer in BRCA1 mutation carriers
Parameters Cancer patients Control group OR 95% CI p
(n = 150) (n = 150)
Year of birth 1951.8 1951.7 0.95
Age at diagnosis 47.5
Age at menarche 13.7 14.0 0.9a 0.8-1.0 0.09
Parity 2.0 2.2 0.9b 0.7-1.2 0.35
Cigarette smoking 49% 45% 1.3 0.8-2.3 0.25
Coffee consumption 73% 77% 0.7 0.4-1.3 0.21
Oophorectomyc 2.0% 3.7% 0.4 0.1-1.1 0.08
Breast-feeding:
never 22% 19%
≤1 year 58% 58% 1.0 0.5-1.9 0.97
>1 year 20% 23% 1.0 0.4-2.6 0.97
Contraceptives:
never 92% 86%
ever 8% 14% 0.4 0.2-1.0 0.04
ever ≤2 years 6% 4% 0.8 0.2-2.5 0.69
ever >2 years 2% 10% 0.2 0.1-0.7 0.01
CI – confidence interval; n – number of cases; OR – odds ratio; p – statistical significance.
a – per additional year; b – per additional birth; c – prior to diagnosis of breast cancer.
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analysis on living women, and because risk factor
information was obtained by questionnaire.
The frequency of tamoxifen use was compared
between the bilateral cases and unilateral matched
controls. The odds ratio for contralateral breast cancer
associated with tamoxifen use were adjusted for the other
covariates, including other treatments received
(radiotherapy and chemotherapy), smoking (ever/never),
parity and oral contraceptive use (ever/never). To
estimate the protective effect of tamoxifen separately for
BRCA1 and BRCA2 carriers, and for women with and
without oophorectomy, estimates were generated for
these subgroups using the matched subsets. All
calculations were done using the SAS Statistical Package.
The study was approved by the ethics board of the
University in Toronto.
Results 
Tamoxifen use was reported by 12.3% of the
bilateral cases and by 24.6% of the unilateral controls
(p=0.001). The univariate odds ratio for tamoxifen use
and contralateral breast cancer was 0.45. The results
of the multivariate analysis were similar. The protective
effect of tamoxifen was similar in both BRCA1 and
BRCA2 carriers; among the BRCA1 cases and matched
controls, the univariate odds ratio was 0.48 and among
the BRCA2 carriers the odds ratio was 0.39 (Table 7).
Cases and controls were matched for oophorectomy
status. This was done to evaluate the protective effect of
tamoxifen separately for women with and without intact
ovaries. The results suggest that tamoxifen is protective
against contralateral breast cancer in women with intact
ovaries (OR=0.44). A protective effect was not observed
among women who had undergone oophorectomy
(OR=0.87) – Table 8.
It is also of interest to establish whether tamoxifen
is protective after natural menopause. The observed
protective effects of tamoxifen were similar for women
who were diagnosed with their first breast cancer before
menopause (OR=0.54) and those initially diagnosed
after menopause (OR=0.33) – Table 9. 
There did not appear to be any residual protection
offered by tamoxifen beyond 10 years of the first breast
cancer diagnosis (Table 10).
Assessment of the probability of transmission of the mutant
BRCA1 allele to offspring of the mutation carrier
(based on publication: A. Gronwald J et al. Non-random
transmission of mutant alleles to female offspring of BRCA1 carriers
in Poland. J Med Genet 2003; 40: 719-720. B. Gronwald J et al.
Transmission of mutant alleles to female offspring of BRCA1 carriers
in Poland. J Med Genet 2005; 42: e40)
A. Constitutional mutations in the BRCA1 gene
predispose to an autosomal dominant syndrome of breast
Table 7. Relationship between tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Parameters Case Control Univariate analysis Multivariate analysis
(n = 285) (n = 751)
OR 95% CI p OR 95% CI p
All carriers: tamoxifen, n
never 250 566 1.00 1.00
ever 35 185 0.45 0.29-0.70 0.0004 0.47 0.30-0.74 0.001
BRCA1 carriers: tamoxifen, n
never 204 483 1.00 1.00
ever 24 138 0.48 0.29-0.79 0.004 0.50 0.03-0.85 0.01
BRCA2 carriers: tamoxifen, n
never 46 83 1.00 1.00
ever 11 48 0.39 0.16-0.94 0.003 0.42 0.17-1.02 0.05
Table 8. The effect of tamoxifen on the risk of contralateral breast
cancer by oophorectomy status (multivariate analysis)
Parameters n OR 95% CI p
Oophorectomy 26 0.83 0.24-2.89 0.7700
No oophorectomy 259 0.44 0.27-0.65 0.0009
CI – confidence interval; n – number of cases; OR – odds ratio; p – statistical 
significance.
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and ovarian cancer [3]. It is expected that 50% of the
daughters of women who carry a mutation in BRCA1
should be carriers of this mutation based on the principles
of Mendelian transmission. At birth, it is expected that
50% of the children of a carrier parent will inherit 
a mutant allele. If the mortality in carriers is higher in
carriers than in noncarriers, then the proportion of carriers
among offspring is expected to decline with age. Similarly,
among unaffected women, the proportion of carriers is
expected to decline with age. Taking into account these
theoretical assumptions, cancer risk for relatives of cancer
patients as well as penetrance of the BRCA1 gene are
calculated [32, 33]. In this work empirical evaluation of
this hypothesis was performed. 
Materials and methods
In total, 387 carrier probands (drawn from three
sources: (a) 44 carrier probands were found in 
490 consecutive cases of breast cancer diagnosed in
women under 50 years of age; (b) 46 carrier probands
were found in 347 consecutive ovarian cancer cases
diagnosed at any age; and (c) 297 carrier probands
were found among women with a family history of
breast or ovarian cancer who were referred for genetic
counselling) were identified, of whom 247 had one or
more daughters. To avoid the possibility of selection
bias we included only families in which the mothers
received their genetic test result before any of the
daughters were tested (218 of 247). Of these 218, 91
mothers had one or more daughters who were tested
for the mutation and 127 had daughters who were not
tested. The 91 carrier mothers had 141 daughters, of
whom 126 were tested (range 1-4 daughters per
mother). Four of the daughters had been affected by
breast cancer and were excluded. The study was
approved by the ethics board of the Pomeranian
Medical University in Szczecin.
Results 
The mean age of the daughters was 26.5 years
(range 7-50 years) (mutation results were not offered
to daughters under the age of 18 years). The
prevalence of mutations in the daughters by age is
given in Table 11.
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Table 9. The effect of tamoxifen on the risk of contralateral breast cancer by menopausal status (univariate analysis)
Parameters n OR 95% CI p
Both cancers premenopausal 86 0.31 0.11-0.82 0.02
A. All carriers: 259 0.44 0.27-0.65 0.0009
– Pre- and postmenopausal 114 0.54 0.27-1.05 0.07
– Both cancers postmenopausal 37 0.33 0.11-1.01 0.05
B. Natural menopause only:
– Pre- and postmenopausal 22 0.13 0.02-1.10 0.06
– Both cancers postmenopausal 13 0.45 0.09-2.37 0.34
CI – confidence interval; n – number of cases; OR – odds ratio; p – statistical significance.
Table 10. The effect of tamoxifen on the risk of contralateral breast cancer depending on time from first breast cancer (univariate analysis)
Years since diagnosis  1-5 years 5-10 years >10 years
of first primary breast cancer
Tamoxifen, any use, n n = 168 n = 68 n = 49
RR 95% CI p RR 95% CI p RR 95% CI p
Never 1.00 1.00 1.00
Ever 0.46 0.27-0.79 0.005 0.42 0.16-1.10 0.08 0.99 0.13-7.61 0.99
CI – confidence interval; n – number of cases; OR – odds ratio; p – statistical significance.
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In total, 75 of 122 unaffected daughters (61.5%)
were carriers of the mutation; 61 would have been
expected under a transmission ratio of 50% (p=0.011).
Surprisingly, there was no evidence of declining
prevalence of mutations with increasing age of the
daughters.
Results were similar for each of the three groups of
probands. Among the tested daughters of the
unselected cases of breast cancer 18 mutations were
observed (15 expected), among the daughters of the
unselected cases of ovarian cancer 12 mutations were
observed (nine expected), and among the daughters
of the mothers referred to the genetics clinics 
45 carriers were observed (37 expected).
Results were similar for the three mutations studied:
among daughters of mothers with the 5382insC
mutation 46 carriers were observed (36.5 expected);
among daughters of mothers with the G61C mutation 
16 mutations were observed (12.5 expected); and
among daughters of mothers with the 4153delA mutation 
13 mutations were observed (12 expected). For
comparison purposes, we also tested 63 sons of the carrier
mothers; 30 mutations were found (31.5 expected).
B. Two years after the publication of Gronwald et
al. [34], similar studies were made by de la Hoya et
al. [35] in a Spanish and Dutch cohort, which also
observed a higher ratio of carrier daughters (58% in
those under 30 years of age). However, Evans et al.
found no evidence of non-random transmission in an
English cohort [36]. Because of the potential
importance of these observations for genetic
counsellors and for our understanding of BRCA1
genetics, we repeated this study on an unselected series
of breast cancer patients. This study is superior in
design to our earlier study in that the mutation carriers
were drawn from a pool of unselected breast cancer
patients and all first-degree relatives were accounted
for and offered genetic testing.
Materials and methods
In the course of a national breast cancer survey we
identified 4596 women with breast cancer diagnosed
before age 50 from 1996 to 2003 at one of 18 centres
situated throughout Poland. We were able to obtain 
a DNA sample for 2871 of these patients for BRCA1
analysis. Among these women 154 mutation carriers
were identified (5.4%). Through pedigree review, 
we identified 187 sisters and 134 daughters of these
154 women. We requested a blood sample from all
female first-degree relatives. We completed testing on
125 sisters (69% of total sample) and 109 daughters
(81%). The study was approved by the ethics board of
the Pomeranian Medical University in Szczecin.
Results 
The BRCA1 mutation was present in 57 of the 
109 daughters (52%) and in 67 of the 125 (54%)
sisters. Of the 125 sisters, 41 had breast cancer (22%).
Of these, 23 were tested and 22 were found to be
positive. The other 146 sisters were unaffected; of these,
102 were tested and 45 (43%) were positive. Assuming
the same distribution of carriers and non-carriers in the
62 untested sisters (18 affected and 44 unaffected), we
estimate that 103 of the sisters were positive for the
family mutation and 84 were negative (p=0.08). The
estimated transmission ratios for daughters was 52%
and for sisters 55%. Among women in the first study
who were born between 1971 and 1980, there were
38 carriers and 18 noncarriers (transmission ratio 68%).
In the present study the proportion was 60% (33 of 55).
When the data from the two independent studies were
merged, the possibility of an effect by calendar year was
supported to a modest degree (Table 12). However,
there is no consistent trend here; this was a post hoc
comparison, and there were no significant differences
between the rows.
Table 11. Mutation frequency by age among unaffected daughters of
BRCA1 mutation carriers
Age group Number Number Percentage p
of carriers of non-carriers of carriers 
(%)
0-19 12 14 46.0 0.600
20-29 38 18 68.0 0.008
30-39 16 10 61.5 0.240
40-50 9 5 64.0 0.290
Total 75 47 61.5 0.011 
Table 12. Number by age of mutation positive and negative first-degree
female relatives of BRCA1 mutation carriers (both studies together)
Year of birth Number Number of Transmission p
of carriers non-carriers ratio (%)
<1950 10 11 48 0.800
1951-1960 40 29 58 0.300
1961-1970 36 28 56 0.300
1971-1980 71 40 64 0.003
>1981 42 49 46 0.900
Total 199 157 56 0.030
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Assessment of the male to female ratio in offspring of BRCA1
mutation carriers
(based on publication: Gronwald J et al. Male to female ratio among
offspring of BRCA1 mutation carriers. Breast Cancer Res Treat 2006;
97: 113-114)
To the editor: It has been reported that the RING
domain of BRCA1 protein interacts with the Xist RNA in
mammalian cells, thereby influencing X chromosome
inactivation [37]. Lee et al. showed that in mice, defective
X-chromosome inactivation changes the sex ratio of
offspring [38]. In this context it has been suggested that
BRCA1 insufficiency may reduce the ability of Xist RNA to
accumulate along the X chromosome and lead to 
a skewed sex ratio in children [39]. In light of these
findings, we were interested in the results of de la Hoya
and colleagues, who reported an increased ratio of female
to male offspring of BRCA1 mutation carriers, but not of
BRCA2 mutation carriers [40]. It is well known that studies
such as these may be influenced by possible ascertainment
biases [45], in particular if women with daughters are
more likely to seek genetic testing than women with only
boys or with no children. Recently, several authors
observed only slight, statistically insignificant excesses of
female offspring of BRCA1 or BRCA2 carriers, suggesting
that the observed sex ratio skew against male births might
be due to ascertainment bias [41-44]. Studies in which
BRCA carriers are ascertained within a consecutive series
of breast or ovarian cancer cases, and are unselected for
family histories and for sex distribution of children, are
ideally suited to study this question as they are free from
ascertainment bias [35].
Materials and methods
In the course of a national breast cancer survey,
through cancer registries of pathology departments we
identified 4596 consecutive women with breast cancer
diagnosed before age 50 at one of 18 centres situated
throughout Poland from 1996-2003. In each centre
affected women offered blood for genetic testing. We
were able to obtain a DNA sample for BRCA1 analysis
on 3568 of these patients. Three founder mutations in
the BRCA1 gene (5382insC, C61G, and 4153delA)
which cover about 90% of detectable BRCA1/2
mutations in Poland were studied. Among these women
198 mutation carriers were identified (5.54%). The study
was approved by the ethics board of the Pomeranian
Medical University in Szczecin. 
Results 
Through pedigree review we identified 189 sons and
172 daughters of these 198 BRCA1 mutation carrier
women. The male to female ratio was 1.10. According
to the Polish Main Statistical Office the male to female
ratio in the general population at birth is 1.06 [46]. Thus
the difference is insignificant (ν2=0.08; p=0.77).
Assessment of psychological and medical consequences of
simplified two-stage genetic counselling in females appearing
for BRCA1 gene mutation testing
(based on publication: Gronwald J et al. Direct-to-patient BRCA1
testing: the Twoj Styl experience. Breast Cancer Res Treat 2006; 100:
239-245) 
As the number of preventive options for women at
high risk for hereditary breast cancer expands, the
demand for testing increases. However, many women
do not have ready access to testing because of cost, and
many others have not been recognized by their physicians
to be candidates for testing. There are many effective
methods which allow a reduction of cancer risk for
women with hereditary predispositions for breast or
ovarian cancer [21-25, 29, 47]. It is a challenge to
identify all women in the population who carry a BRCA1
mutation and provide them proper management. 
To achieve this target many organizational and economic
difficulties must be overcome. Beyond difficulties related
to costs of genetic testing, which substantially vary in
specific populations, there are other obstacles facing: 
(a) mass access to patients who should be offered precise
diagnosis by BRCA1 and BRCA2 testing; (b) proper
concentration of genetic counselling on a group of
patients of the highest cancer risk. 
It is possible to increase women’s awareness about
hereditary cancer through the popular press. On the
other hand oncological geneticians working in the
present obligatory system are unable to provide service
to the increased number of patients. Currently, in most
clinics, women who are to undergo genetic testing
receive at least one personal (one-on-one) counselling
session (or a series of sessions) where they receive
detailed information regarding what to expect in the
event of a positive test. Because personalized counselling
is expensive and time-consuming, testing is usually
restricted to women who have a high chance of carrying
a mutation and who have adequate resources at their
disposal (through private or public means). It is well
known that because of the low number of children in
today’s families, inheritance through the paternal line
and incomplete penetrance, mutation carriers very
frequently come from families with insignificant family
history. Such patients according to frequently applied up
to now indications would never be qualified for genetic
testing. In this work the consequences of an alternative
protocol were studied. In this scenerio information about
hereditary breast/ovarian cancer and genetic testing was
delivered to patients with possible increased cancer risk
Jacek Gronwald
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by the popular press; wide indications for BRCA1 testing
were applied; expanded genetic counselling was limited
to patients with identified BRCA1 mutation or with
pedigree data indicating increased cancer risk.
Materials and methods 
In October 2001 a popular Polish women’s
magazine (Twoj Styl or Your Style) published a supplement
dealing with breast cancer. This is among the best known
women’s magazines in Poland and has a circulation of
400,000. The issue contained an article dealing with
issues surrounding hereditary breast cancer, including the
state of genetic testing in Poland and the possible risks
and benefits of genetic testing. Various ways of reducing
cancer risk were described. In collaboration with the
Hereditary Cancer Centre at the Pomeranian Medical
University, the publishers of Twoj Styl offered an
opportunity for 5000 of their readers to participate in
genetic testing at no cost. Women qualified if they were
18 years of age or over and if they had a first- or second-
-degree relative with breast cancer before age 50 or
ovarian cancer at any age, or if they themselves had such
history of breast or ovarian cancer. Readers who qualified
could clip a coupon inviting them for genetic testing and
present the coupon at one of 20 familial cancer
outpatient clinics situated throughout the country. When
the woman arrived at the clinic she presented her coupon
and her indications for testing were confirmed by the local
staff. If she qualified she signed a consent form and she
gave a blood sample for testing. A brief intake form was
completed regarding family history and personal history
of cancer. Genetic testing was done for the three founder
BRCA1 mutations which are common in the Polish
population. A total of 5024 tests were completed between
November 2001 and February 2002 at the Hereditary
Cancer Centre in Szczecin. Out of these, 198 women
(3.9%) were found to carry a BRCA1 mutation, and 1760
women (35%) had stronger family predisposition to breast
and/or ovarian cancer. In these patients expanded genetic
counselling providing detailed information about cancer
risk and preventive options was carried out. Other patients
obtained expanded genetic counselling if they wished. 
Investigation report
A questionnaire was sent to a sample of the study
subjects approximately 1 year after they received the
test result. The questionnaire dealt with the knowledge
of the test results and the satisfaction with the testing
process (available upon request). Women were asked
whether or not they valued the testing process and
whether they were satisfied with their decision to
participate. Women were questioned about cancer
prevention practices over the past year. Questionnaires
were sent to all 198 women with a positive genetic
result and to a random sample of 280 women without
mutations. The study was approved by the ethics board
of the Pomeranian Medical University in Szczecin.
Results 
Among the 5024 women who received testing 
198 BRCA1 mutations were identified (3.9%). A question-
naire was received from 126 women with a positive
genetic test result (72%). Six carrier women had died
and two refused. Twenty-six women were lost to follow-
up and 15 did not respond. Of the 126 carriers who
responded, 63 women had a past history of cancer
and 63 had no history of cancer. A random sample of
280 non-carriers was selected. Of these 173 (62%)
returned the questionnaire. Twenty-eight of these (16%)
had a past history of breast or ovarian cancer and 
145 had no history of cancer.
Upon receiving a positive test result the most
common immediate reactions among mutation carriers
were worry (36.5%), shock (27%) and sadness (22%).
Among non-carriers the most common reactions were
relief (63.5%) and happiness (29.5%).
On average, carriers estimated their lifetime risk of
breast cancer to be 60.5% and of ovarian cancer to be
48%. Non-carriers with a strong family history estimated
their lifetime risk for breast cancer to be 29% on
average and estimated their lifetime risk of ovarian
cancer to be 22%. Non-familial non-carriers estimated
their breast cancer risk on average to be 13% and their
ovarian cancer risk to be 8.5%. On average, carriers
used preventive measures more frequently than non-
-carriers (Table 13).
Approximately two-thirds of the carriers and just
over one-half of the familial non-carriers had complied
with the annual recommendations for breast cancer
screening. Compliance was much less for ovarian
cancer prevention.
Satisfaction rates among the subjects were very
high. 98% of the women indicated that they would
recommend genetic testing to other women in their
position. The proportion of satisfied women was equally
high among carriers (98%) and non-carriers (97%).
Summary of the results
1. The risk of breast and ovarian cancer in first-degree
relativities of women with BRCA1 mutation depends
on mutation type, and is higher in the younger
generation. Additionally, the cancer site diagnosed
in the proband influences the risk of breast cancer,
but not necessarily for ovarian cancer. 
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2. In BRCA1 mutation carriers from Poland:
a) delay of menarche, long-term breast-feeding and
– with high probability – oophorectomy decreases
the risk of breast cancer;
b) carriers who had more children were significantly
more likely to develop breast cancer;
c) long-term use of oral contraceptives decreases
the ovarian cancer risk;
3. Risk of contralateral breast cancer was reduced by
more than 50% in carriers of BRCA1 and BRCA2
mutations when tamoxifen was given. Protective effects
of tamoxifen were observed in carriers before
menopause and those after menopause. There did
not appear to be any residual protection offered by
tamoxifen beyond 10 years of the first breast cancer
diagnosis. 
4. Probably there is slight preferential transmission of
the mutated allele to daughters of BRCA1 carriers.
In two independent studies, similar differences in
transmission of the mutated allele, especially among
children born in the 1970s, were observed
5. Among children of carriers with the BRCA1 mutation,
the proportion of boys and girls is as in the whole
population. 
6. First psychological reactions after receiving information
about being a carrier of BRCA1 mutation are negative.
Identification of high cancer risk increase use of
prophylactic measures. 98% of BRCA1 carriers
identified during action initiated by mass media would
recommend testing for people in a similar life situation.
Conclusions
1. BRCA1 mutation type and tumour location in the
proband should be considered in the evaluation of
breast or ovarian cancer risk. Probably, there are
modifying genes influencing BRCA1 mutation
penetrance.  
2. Long-term breast-feeding, intensive physical exercise
which delays first menarche, prophylactic adnexectomy
and use of contraceptives at the appropriate age
should be presented to BRCA1 mutation carriers as
options decreasing breast and/or ovarian cancer risk. 
3. In the case of patients with breast cancer and without
oophorectomy, use of tamoxifen should be presented
to BRCA1 and BRCA2 mutations carriers as a preven-
tive treatment of contralateral breast cancer. 
4. Environmental conditionings should be taken into
consideration as a reason for changes in transmission
degree of the mutant allele of BRCA1.
5. An effect of female carrier state of BRCA1 on male
to female ratio among offspring is unlikely. 
6. To increase access to BRCA1 testing simplified two-
-step genetic counselling may be considered.
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